We report on a new straightforward magnetic cell-labeling approach that combines three US Food and Drug Administration (FDA)-approved drugs-ferumoxytol, heparin and protamine-in serum-free medium to form self-assembling nanocomplexes that effectively label cells for in vivo magnetic resonance imaging (MRI). We observed that the ferumoxytol-heparin-protamine (HPF) nanocomplexes were stable in serum-free cell culture medium. HPF nanocomplexes show a threefold increase in T2 relaxivity compared to ferumoxytol. Electron microscopy showed internalized HPF in endosomes, which we confirmed by Prussian blue staining of labeled cells. There was no long-term effect or toxicity on cellular physiology or function of HPFlabeled hematopoietic stem cells, bone marrow stromal cells, neural stem cells or T cells when compared to controls. In vivo MRI detected 1,000 HPF-labeled cells implanted in rat brains. This HPF labeling method should facilitate the monitoring by MRI of infused or implanted cells in clinical trials.
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Cell-based therapies have become a major focus in regenerative medicine and tumor trials [1] [2] [3] . To understand the effects of cellular therapies, noninvasive imaging approaches have been developed that would allow for the monitoring of the migration of cell products 4 . Currently, cell-trafficking studies in the clinic depend on either radiolabeling of cells or the addition of reporter genes into the cell genome coupled with a radionuclide or positron-emitting probe for imaging, most of which require approval by the FDA [4] [5] [6] . Possible limitations of these approaches include the short half-life of isotopes, the possibility of renal toxicity, leakage of the radioactive label or insertion of viral particles into random tissues 4, 5 . MRI coupled with magnetically labeled cells provides an excellent alternative method of tracking cells because of its inherent soft-tissue contrast, high spatial resolution and lack of ionizing radiation 4, 7 .
Clinically approved superparamagnetic iron oxide nanoparticles (SPIONs) are used to treat iron-deficiency anemia [8] [9] [10] [11] , and they have been used as contrast agents to detect pathology 7, 12, 13 or visualize transplanted cells 7 . SPIONs are usually coated with carbohydrate dextran and are biodegradable 14 . Various methods [15] [16] [17] [18] [19] [20] [21] have been developed to label cells with SPIONs providing the ability to monitor transplanted cells by MRI. To facilitate the translation of magnetic resonance tracking as part of the cellular therapy, techniques were developed combining clinical-grade SPIONs-ferumoxides-with protamine to label cells without short-or long-term toxicity or alteration in their functional capacity or stemness 16, 22, 23 . However, ferumoxides and similar SPIONs were removed from the market, thus halting the progress toward translating the use of clinically approved agents for labeling and tracking cells by MRI for clinical trials.
Recently, ferumoxytol, a semisynthetic carbohydrate non-dextrancoated ultrasmall SPION (USPIO), has been approved for the treatment of iron-deficiency anemia in chronic kidney disease [8] [9] [10] [11] 13 . Ferumoxytol has been used in experimental and clinical trials as a macrophage-imaging agent as well as a blood-pool agent with MRI 13, 24 . Ferumoxytol alone or in combination with protamine does not effectively label cells 10, 11, 13 .
The purpose of this study is to report on a new, straightforward approach using three FDA-approved drugs (albeit off label)ferumoxytol, heparin and protamine-to label cells for MRI, with potential implications for cell-based therapy. Heparin is an anticoagulant, and protamine is used to reverse heparin's anticoagulation effects. Heparin and protamine form nanocomplexes in vitro and in vivo through electrostatic interactions 25 and have been used to facilitate intracellular drug delivery 26, 27 . Combining heparin, protamine and ferumoxytol results in the formation of a self-assembling nanocomplex (HPF) that we have characterized and used to label stem cells or immune cells for MRI. Labeling cells with HPF was nontoxic to cells, and this should facilitate the rapid translation of this technique to clinical trials.
The HPF nanocomplexes at the ratio of heparin (2 IU ml −1 ): protamine (60 µg ml −1 ): ferumoxytol (50 µg ml −1 ) used to magnetically label cells had a zeta potential (ζ) of 14.1 ± 3.43 mV and size of 204 nm in water and a ζ of −10.9 ± 0.0 and size of 153.6 nm in RPMI at 37 °C ( Fig. 1a and Supplementary Table 1 ). Transmission electron microscopy (TEM) micrographs of the HPF nanocomplexes show ferumoxytol as electron-dense iron nanoparticles that coat the clear heparin-protamine aggregates in an ovoid shape of approximately 150-200 nm in diameter ( Fig. 1b,c) .
Cell labeling and iron content
Approximately 100% of the HPF-labeled cells were Prussian blue positive or 3,3-diaminobenzidine-enhanced Prussian blue (PB-DAB) positive on histology ( Fig. 2a-j) . We confirmed the internalization of HPF in endosomes by TEM ( Fig. 3) , with HPF appearing as electrondense iron oxide nanoparticles of ~6-8 nm in size. We did not observe HPF on the cell membrane following cell washes. To determine the longevity of intracellular iron, we labeled neural stem cells (NSCs), bone marrow stromal cells (BMSCs) and T cells with HPF and allowed them to either proliferate and divide or grow to confluence, exhibiting contact inhibition. We stained the labeled cells at multiple time points to determine the presence of intracellular iron ( Supplementary  Figs. 1 and 2) . Prussian blue-positive T cells, NSCs or BMSCs were present at 7 d or 14 d when repeatedly cultured, whereas PB-DABpositive cells were present for 21 d (NSCs) and 28 d (BMSCs) when cells were grown to confluence.
The average iron content per cell was as follows: BMSCs = 2.12 ± 0.11 pg; NSCs = 2.8 ± 1.19 pg; hematopoietic stem cells (HSCs) = 1.33 ± 0.2 pg; T cells = 0.73 ± 0.25 pg; monocytes = 2.56 ± 1.1 pg. The iron content of unlabeled cells was 0.0-0.5 pg per cell, a value that was significantly different from that of labeled cells (P < 0.05). We were unable to label cells with ferumoxytol alone or when combined with protamine over a wide range of ratios.
HPF cells: toxicity, phenotype, differentiation and function
There were no substantial differences in the rate of apoptosis, increases in reactive oxygen species (ROS), viability or proliferation 1-4 d after labeling with HPF for all cell types as compared to controls ( Fig. 4) .
There was a slight decrease in numbers of NSCs (6%) and T cells (10%) immediately after cell collection ( Fig. 4a ) and in proliferation (MTS, see Supplementary Methods) of NSCs and HSCs at day 4 compared to control cells (Fig. 4b) . The proliferative capacity recovered overtime when the cells were assessed at day 7 for NSCs and day 30 for HSCs. Phenotypic analyses of HPF-labeled and unlabeled BMSC surface markers were positive for surface markers CD90, CD73 and CD105 (Supplementary Fig. 3 ). In this study, we used HPF-labeled BMSCs that were cryopreserved and subsequently thawed for analysis. These results revealed that there were no effects on cellular viability ( Supplementary  Fig. 3a ) or surface markers ( Supplementary Fig. 3b-d ) after a freezethaw cycle, indicating that it is not necessary to immediately label cells before use. The differentiation potential of HPF-labeled BMSCs toward adipogenic and osteogenic lineages showed no differences when compared to controls (Supplementary Fig. 4 ). There were no differences in chemotaxic migration toward tumor-conditioned medium or stromal cell-derived factor-1α (SDF-1α) when comparing HPF-labeled BMSCs or NSCs to unlabeled controls ( Supplementary Fig. 5) . In vivo MRI In vivo magnetic resonance images of a rat brain with intracerebral implantation of HPF-labeled BMSCs, obtained at a clinically relevant field strength of 3 tesla (T), showed hypointense voxels at the injection sites that received 1 × 10 3 to 1 × 10 4 labeled BMSCs compared to the surrounding parenchyma or to unlabeled cells (Fig. 5) . Implanted HPF-labeled cells were detectable because of T2 and T2* shortening (Fig. 5a) . Calculated T2* maps at day 8 showed a substantial (30-60%) decrease in T2* values for the 1 × 10 3 to 1 × 10 4 labeled cells (T2* = 30.9-34.3 ms) compared to the surrounding brain (T2* = 67.5 ms) and unlabeled cells (T2* = 48.0 ms) ( Fig. 5b) . HPF-labeled BMSCs implanted at 1 × 10 3 cells and 5 × 10 3 cells seemed to have shorter T2* values (32.9 ms and 30.9 ms, respectively) compared to 10 4 HPFlabeled cells (34.3 ms) (Fig. 5b) . This lack of correlation between the number of HPF-labeled BMSCs and T2* change at the injection site of 1 × 10 4 HPF-labeled cells was possibly due to the volumetric effect at the MRI slice (that is, 500 µm) shown or unequal distribution of the density of HPF-labeled cells at the injection site. Moreover, the quantification of the numbers of labeled cells from R2* measurements is inexact, especially when monitoring cells overtime, owing to hemorrhage, dead cells, cell density and iron load or susceptibility effects between tissues 4, 30 . Photomicrographs of the area of the brain implanted with 1 × 10 3 HPF-labeled BMSCs showed colocalization of antibody stains for human mitochondria with multiple PB-DABpositive human BMSCs (Fig. 5c,d) .
DISCUSSION
The major finding of this study is the formation of self-assembling HPF nanocomplexes by simply combining three FDA-approved drugs-ferumoxytol, heparin and protamine-directly into medium containing cells, resulting in the labeling of stem cells and immune cells for cellular tracking and detection by MRI. Combining protamine with ferumoxytol resulted in the formation of large, polydisperse complexes that were not incorporated into cells. Previous work has shown that protamine-ferumoxytol complexes were unable to label rat blood mononuclear cells 13 . Although it is counterintuitive to add heparin to protamine-ferumoxytol to facilitate endosomal incorporation in cells, the addition of heparin gives rise to the formation of HPF nanocomplexes that are endocytosed by cells.
Heparin-based nanoparticles self-assemble with various cationic molecules and have been used for drug delivery, for tissue engineering and for prolonging the circulating half-life of an agent 26, 28, 31 . When heparin and protamine are mixed together, they rapidly form complexes through electrostatic interactions 25, 26, 29 . We observed that, in RPMI, heparinprotamine complexes form and then attract ferumoxytol, resulting in stable HPF nanocomplexes. Mixing HPF in an alternative order, such as ferumoxytol, heparin and then protamine, also results in nanocomplexes that can be used for cell labeling; however, other combinations of the drugs (for example, protamine, ferumoxytol and then heparin) did not effectively or efficiently label all cell types (data not shown) 32 . TEM of heparin-protamine aggregates coated with colloidal iron showed a dense ring of iron around a heparin-protamine hypodense center 29 , which is similar to what is observed for HPF nanocomplexes. Further investigation is required to elucidate the ultrastructure and chemical composition of the HPF nanocomplexes to achieve effective iron loading of cells while preserving cell viability and function.
Heparin, protamine and ferumoxytol are routinely used for specific clinical indications. The concentrations of heparin, protamine and ferumoxytol used in this study result in intracellular concentrations of each drug that were substantially below recommended clinical doses. The HPF nanocomplexes have similar biochemical properties to SPIONs, which have been shown to label cells and biodegrade through the iron metabolic pathway 16, 22, 23, 33 . We have also shown that HPF-labeled NSCs and BMSCs remained Prussian blue positive for up to 28 d, similar to what is observed in stem cells labeled with SPIONs 16, 33 . Although further investigation is needed to determine npg any potential toxicity of delivering HPF-labeled cells in vivo, ferumoxytol is likely to be metabolized in a similar way to other SPIONs.
As with previous findings of SPION-labeled cells, dilution of the endosomal HPF nanocomplexes is likely to occur through cell division or by digestion 34, 35 .
In this study, we could clearly visualize as few as 1,000 cells at 8 d after intracerebral transplantation on T2*-weighted images, owing to T2* shortening and the susceptibility blooming artifact associated with the HPF-labeled cells at 3 T. The intracellular location of HPF nanocomplexes results in T2* shortening of water protons by causing magnetic field gradients in the region of interest. Hemorrhage at the site of injection may also cause T2* shortening and represents a limitation of interpreting MRI cell-tracking studies of SPION-labeled cells 4, 14, 16 . Although the labeled cell death will occur over time, we previously reported that ~10-20% of the iron label in transplanted cells may be endocytosed by activated macrophages but these phagocytic cells contributed minimally to the signal in the hypointense voxels on MRI 36 . The T2*-weighted images used in this study allowed for short acquisition times (approximately 10 min) without modification to the clinical magnetic resonance scanner. Although the intracellular concentration of iron of HPF-labeled stem cells was less than that of cells labeled with SPIONs, the iron content is comparable to that reported for cells labeled with other USPIO nanoparticles 15, 18, 21, 37, 38 . The intracellular iron content is dependent on the cell surface area and nuclear-to-cytoplasmic ratio, with larger cells having the potential to uptake greater amounts of SPIONs 4, 16 .
With the removal of the clinically available SPION contrast agents from the market, cell therapy trials that planned to incorporate magnetic cell labeling to monitor cell migration were placed on hold or abandoned. Ferumoxytol is the only intravenous FDA-approved USPIO nanoparticle preparation that can be used to magnetically label and monitor the temporal spatial migration of infused or implanted cells by MRI. One of the main advantages of complexing ferumoxytol with heparin and protamine to label cells is that these drugs are used clinically; therefore, extensive safety testing of the drugs should not be necessary, and the time required for evaluating HPF for an investigative new drug application should be shortened. Although standard operating-procedure protocols will need to be developed, the HPF labeling method presented here allows for easy scale-up for cell labeling in current good-manufacturing-practice cell-processing facilities. Further optimization of the HPF protocol by modifying the amount of heparin (to 1-3 IU ml −1 ) or protamine (to 30-60 µg ml −1 ) or by increasing the amount of ferumoxytol (to 50-100 µg ml −1 ) may result in higher intracellular iron concentrations, providing the basis for the rapid translation into clinical trials.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
